However, some studies report that pemetrexed is a substrate of ABCG2 [12,13], which implies that blocking ABCG2-mediated active efflux function might substantially contribute to increased response rates and prolonged survival in patients with NSCLC [14]. Here, ABCG2 is linked to non-small cell lung carcinoma.